MA37879B1 - Forme amorphe stabilisée d'agomélatine, procédé pour sa préparation et compositions pharmaceutiques la contenant - Google Patents

Forme amorphe stabilisée d'agomélatine, procédé pour sa préparation et compositions pharmaceutiques la contenant

Info

Publication number
MA37879B1
MA37879B1 MA37879A MA37879A MA37879B1 MA 37879 B1 MA37879 B1 MA 37879B1 MA 37879 A MA37879 A MA 37879A MA 37879 A MA37879 A MA 37879A MA 37879 B1 MA37879 B1 MA 37879B1
Authority
MA
Morocco
Prior art keywords
agomelatine
preparation
amorphous form
pharmaceutical compositions
compositions containing
Prior art date
Application number
MA37879A
Other languages
English (en)
Other versions
MA37879A1 (fr
Inventor
David Lafargue
Michael Lynch
Cécile Poirier
Philippe Letellier
Jean-Manuel Pean
Ying Luo
Hanbin Shan
Yuhui Shen
Original Assignee
Servier Lab
Shanghai Inst Pharmaceutical Ind
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/EP2013/068792 external-priority patent/WO2014041015A1/fr
Application filed by Servier Lab, Shanghai Inst Pharmaceutical Ind filed Critical Servier Lab
Publication of MA37879A1 publication Critical patent/MA37879A1/fr
Publication of MA37879B1 publication Critical patent/MA37879B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Inorganic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Cardiology (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention concerne une forme amorphe stabilisée d'un composé de formule i) : l'invention concerne également des médicaments.
MA37879A 2012-09-11 2015-02-27 Forme amorphe stabilisée d'agomélatine, procédé pour sa préparation et compositions pharmaceutiques la contenant MA37879B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/CN2012/081250 WO2014040228A1 (fr) 2012-09-11 2012-09-11 Forme amorphe stabilisée de l'agomélatine, son procédé de préparation et compositions pharmaceutiques la contenant
PCT/EP2013/068792 WO2014041015A1 (fr) 2012-09-11 2013-09-11 Forme amorphe stabilisée d'agomélatine, procédé pour sa préparation et compositions pharmaceutiques la contenant

Publications (2)

Publication Number Publication Date
MA37879A1 MA37879A1 (fr) 2016-06-30
MA37879B1 true MA37879B1 (fr) 2017-01-31

Family

ID=50277476

Family Applications (1)

Application Number Title Priority Date Filing Date
MA37879A MA37879B1 (fr) 2012-09-11 2015-02-27 Forme amorphe stabilisée d'agomélatine, procédé pour sa préparation et compositions pharmaceutiques la contenant

Country Status (2)

Country Link
MA (1) MA37879B1 (fr)
WO (1) WO2014040228A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012093402A1 (fr) * 2011-01-04 2012-07-12 Symed Labs Limited Procédés pour la préparation de n-[2-(7-méthoxy-1-naphtyléthyl]acétamide
CN109589313A (zh) * 2017-10-01 2019-04-09 万特制药(海南)有限公司 阿戈美拉汀分散片及其制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101836966A (zh) * 2010-05-27 2010-09-22 北京万全阳光医药科技有限公司 一种含有阿戈美拉汀的口腔崩解片
WO2012093402A1 (fr) * 2011-01-04 2012-07-12 Symed Labs Limited Procédés pour la préparation de n-[2-(7-méthoxy-1-naphtyléthyl]acétamide
WO2012130837A1 (fr) * 2011-03-28 2012-10-04 Ratiopharm Gmbh Agomélatine solide sous une forme non cristalline
CN102716493B (zh) * 2011-03-31 2014-05-28 天津药物研究院 含无定型态阿戈美拉汀的共聚物、其制备方法、其药物组合物及用途
CN102670514B (zh) * 2012-04-29 2017-05-10 浙江华海药业股份有限公司 阿戈美拉汀固体制剂

Also Published As

Publication number Publication date
MA37879A1 (fr) 2016-06-30
WO2014040228A1 (fr) 2014-03-20

Similar Documents

Publication Publication Date Title
MA42231B1 (fr) Nouveaux dérivés d'hydroxyacide, leur procédé de préparation, et compositions pharmaceutiques les contenant
MA42230B1 (fr) Dérivés bicycliques, leur procédé de préparation, et compositions pharmaceutiques les contenant
GEP20146146B (en) Pyrrolopyrimidine compounds as inhibitors of cdk4/6
MX2015003653A (es) Derivados de amida del acido benzoimidazol-carboxilico como moduladores del receptor apj.
MA37519A1 (fr) Composés et compositions pour inhiber l'activité d'abl1, abl2 et bcr-abl1
IN2014MN02106A (fr)
MX2015017861A (es) Derivados de benzotiofeno como inhibidores del receptor de estrogeno.
EA201001682A1 (ru) Производные фенил- и бензодиоксинилзамещенных индазолов
BR112015021983A2 (pt) compostos heterocíclicos e usos dos mesmos
MA37400B1 (fr) Composés hétérocyclyle en tant qu'inhibiteurs de mek
MA37866B1 (fr) Dérivés de type aza-indazole ou diaza-indazole pour le traitement de la douleur
GEP20217235B (en) Processes for preparing quinoline compounds and pharmaceutical compositions containing such compounds
PH12014501967A1 (en) Benzodioxanes in combination with other actives for inhibiting leukotriene production
UA109199C2 (uk) Дигідропіридинові сполуки, корисні для лікування від залежності, викликаної агентами, що стимулюють вироблення дофаміну
MX2014004858A (es) Compuestos de 3,4-diamino-3-ciclobuten-1,2-diona disustituidos utiles en el tratamiento de patologias mediadas por quimiocinas.
MA37886B1 (fr) Nouvelles pyridinones bicycliques
PH12015502802A1 (en) Formulation comprising a hypolipidemic agent
GEP20166483B (en) Phenyl-3-aza-bicyclo[3.1.0] hex-3-yl-methanones and the use thereof as medicament
MX342924B (es) Nuevos compuestos disustituidos de 3,4-diamino-3-ciclobuteno-1,2-d iona para uso en el tratamiento de patologias mediadas por quimiocinas.
MY167898A (en) Co-crystals and salts of ccr3-inhibitors
MA39165A1 (fr) Dérivés de benzimidazole-proline pour leurs utilisations dans le traitement du syndrome des etats crepusculaires
MY183111A (en) 3-(heteroaryl-amino)-1,2,3,4-tetrahydro-9h-carbazole derivatives and their use as prostaglandin d2 receptor modulators
MA38679B1 (fr) Modulateurs du récepteur de cxcr7
MX364400B (es) Compuestos de tetraciclina.
UA103329C2 (ru) Соли соединений-ингибиторов вич